Skip to main content
. 2022 Oct 1;15(6):535–551. doi: 10.1007/s12195-022-00742-y

Figure 2.

Figure 2

Doxorubicin treatment at an intermediate concentration balances expression of immune suppressive and stimulatory markers on melanoma cells in vitro. B16-F10 cells were seeded in 12-well tissue culture plates, treated with doxorubicin at a range of concentrations for 24 h, and then collected and analyzed. Representative flow cytometry histograms of MHC-I (a), Fas (c), PD-L2 (e), PD-L1 (g), and CD47 (i). Quantification of expression of MHC-I (b), Fas (d), PD-L2 (f), PD-L1 (h), and CD47 (j).